Articles

A new specific peroxisome proliferator-activated receptor (PPAR) modulator has demonstrated promise in a new study reported in November issue of Diabetes.

Takeda Pharmaceutical Company Limited announced today that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

A new specific peroxisome proliferator-activated receptor (PPAR) modulator has demonstrated promise in a new French study, according to a report in the November issue of Diabetes. persons.

In elderly patients with documented coronary heart disease (CHD), statins reduce all-cause mortality, as well as CHD mortality, nonfatal myocardial infarction, the need for revascularization, and stroke, a new review has shown. Investigators say that the magnitude of benefit, with statins reducing all-cause mortality 22%, is larger than previously estimated

Three nights of interrupted slumber upsets young people’s blood sugar levels the same as if they gained 20-30 pounds,, study finds

Currently recommended waist circumference thresholds for identifying people with an increase likelihood of having type 2 diabetes should be modified for Asian and white women and men, a new study suggests.

A new insulin sensitivity index was devised on the basis of an autoregressive model and its validity was investigated.

Researchers report, that a program can be implemented in primary care practices to reduce the mortality among older diabetics who also have a diagnosis of depression.

The primary objective was to determine the prevalence of apathy characterized by loss of initiative and motivation in patients with diabetes.

Treatment with testosterone can reduce the gain in visceral adipose tissue and loss of skeletal muscle seen in non-obese aging men, according to a new report.